Alkermes has reported positive Phase 2 results for its narcolepsy type 1 drug candidate alixorexton, demonstrating statistically significant improvements in wakefulness and reductions in daytime sleepiness across all tested doses. The trial enrolled 92 adults and showed normalization of wakefulness measures after six weeks. Although only one dose cohort showed significant reduction in cataplexy frequency, Alkermes attributes this to methodological limitations and plans to refine assessments in future trials. Alkermes aims to advance alixorexton into Phase 3, setting up competition with Takeda's near-approval orexin-based therapy. CEO Richard Pops highlighted alixorexton's once-daily dosing and potential in multiple indications as strategic advantages over Takeda's twice-daily regimen.